Lilly now expects $91 to $92 billion in revenue this year. Its oral GLP-1 Foundayo brought in $184 million, short of what analysts expected.
Recap by typeshit. Full story at pharmaphorum.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Researchers at nference found pain was the top reason for use and about a third got it from gray-market vendors, while outside experts say benefits remain unproven.
The review lays out how GLP-1 agonists may affect blood pressure and lipid handling, and why that could matter for heart risk.
Loading…